The Deal Register
Database › M&A › HLS Therapeutics Announces Normal Course Issuer Bid

M&A

HLS Therapeutics Announces Normal Course Issuer Bid

Lane
M&A
Announced
23 Jun 2026
Province
Ontario
Industry
Healthcare & life sciences
Status
Announced
What the filing says
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS ), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has filed with the Toronto Stock Exchange (the "TSX"), and the TSX has accepted, the Company's notice of intention regarding a Normal Course Issuer Bid (the "NCIB") for its issued and outstanding common shares (each a "Common Share").
Terms stated
price per security
Source

The terms are in the subscriber edition

This transaction carries 1 stated term, with its value, unit and basis.

Subscribe

Compiled from public filings, court documents, exchange bulletins and issuer releases. Figures are as disclosed and are not independently verified.

Not financial, investment, legal or tax advice, and not an offer to buy or sell any security. Verify everything before you transact.

The Deal Register · Archive · Subscribe